Why is my PPI not working?

CPD
By
AP Staff
-

References

  1. Gastro-oesophageal reflux in adults [published August 2022]. In: Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. At: www.tg.org.au
  2. Daniels B, Schaffer A, Buckley NA, et al. The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: an evaluation using interrupted time series analysis. Pharmacoepidemiol Drug Saf 2022;31(3):370–8.
  3. Fass R. Approach to refractory gastroesophageal reflux disease in adults. UpToDate. Current to September 2023.
  4. MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist’s perspective. Integr Pharm Res Pract 2018;7:41–52.
  5. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10(6):528–34.
  6. Reimer C, Lødrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther 2016;43(8):899–909.
  7. Yadlapati R, Gyawali CP, Pandolfino JE, et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol 2022;20(5):984–94.e1.
  8. Sansom LN, ed. Australian pharmaceutical formulary and handbook. 2024. Gastro-oesophageal reflux; [updated 2023]. At: https://apf.psa.org.au/non-prescription-medicine-guides/gastro-oesophageal-reflux/gather-patient-information
  9. Montoro-Huguet MA. Dietary and nutritional support in gastrointestinal diseases of the upper gastrointestinal tract (I): Esophagus. Nutrients 2022;4819(14):1–24.
  10. Mungan Z, Pinarbasi Simsek B. Which drugs are risk factors for the development of gastroesophageal reflux disease? Turk J Gastroenterol 2020;28(Supp1):S38–S43.
  11. Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. Rapid J Gastroenterol Hepatol 2016;31(4):716–26.
  12. Ionova Y, Ashenhurst J, Zhan J, et al. CYP2C19 allele frequencies in over 2.2 million direct-to-consumer genetics Research participants and the potential implication for prescriptions in a large health system. Clin Transl Sci 2020;13:1298–1306.
  13. RACGP. Genomics in General Practice. (Last updated 12/01/2022).
  14. Spantideas N, Drosou E, Bougea A, et al. Proton pump inhibitors for the treatment of laryngopharyngeal reflux. A systematic review. J Voice 2020;34(6):918–29.